Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17212
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEissmann, Moritz F-
dc.contributor.authorDijkstra, Christine-
dc.contributor.authorWouters, Merridee A-
dc.contributor.authorBaloyan, David-
dc.contributor.authorMouradov, Dmitri-
dc.contributor.authorNguyen, Paul M-
dc.contributor.authorDavalos-Salas, Mercedes-
dc.contributor.authorPutoczki, Tracy L-
dc.contributor.authorSieber, Oliver M-
dc.contributor.authorMariadason, John M-
dc.contributor.authorErnst, Matthias-
dc.contributor.authorMasson, Frederic-
dc.date2018-02-20-
dc.date.accessioned2018-03-12T21:52:46Z-
dc.date.available2018-03-12T21:52:46Z-
dc.date.issued2018-04-
dc.identifier.citationCancer immunology research 2018; 6(4): 409-421en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17212-
dc.description.abstractInterleukin 33 (IL33) is an inflammatory cytokine released during necrotic cell death. The epithelium and stroma of the intestine express large amounts of IL33 and its receptor St2. IL33 is therefore continuously released during homeostatic turnover of the intestinal mucosa. Although IL33 can prevent colon cancer associated with inflammatory colitis, the contribution of IL33 signaling to sporadic colon cancer remains unknown. Here, we utilized a mouse model of sporadic colon cancer to investigate the contribution of IL33 signaling to tumorigenesis in the absence of preexisting inflammation. We demonstrated that genetic ablation of St2 enhanced colon tumor development. Conversely, administration of recombinant IL33 reduced growth of colon cancer cell allografts. In reciprocal bone marrow chimeras, the concurrent loss of IL33 signaling within radioresistant nonhematopoietic, and the radiosensitive hematopoietic, compartments was associated with increased tumor burden. We detected St2 expression within the radioresistant mesenchymal cell compartment of the colon whose stimulation with IL33 induced expression ofbona fideNF-κB target genes. Mechanistically, we discovered that St2 deficiency within the nonhematopoietic compartment coincided with increased abundance of regulatory T cells and suppression of an IFNγ gene expression signature, whereas IL33 administration triggered IFNγ expression by tumor allograft-infiltrating T cells. The decrease of this IFNγ gene expression signature was associated with more aggressive disease in human colon cancer patients, suggesting that lack of IL33 signaling impaired the generation of a potent IFNγ-mediated antitumor immune response. Collectively, our data reveal that IL33 functions as a tumor suppressor in sporadic colon cancer.Cancer Immunol Res; 1-13. ©2018 AACR.en
dc.language.isoeng-
dc.titleInterleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ-Dependent Manner.en
dc.typeJournal Articleen
dc.identifier.journaltitleCancer immunology researchen
dc.identifier.affiliationCancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationSystems Biology and Personalised Medicine Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medical Biology, The University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationInflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australiaen
dc.identifier.affiliationOncogenic Transcription Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Surgery, The University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationSchool of Biomedical Sciences, Monash University, Clayton, Victoria, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australiaen
dc.identifier.doi10.1158/2326-6066.CIR-17-0218en
dc.type.contentTexten
dc.identifier.orcid0000-0002-6399-1177en
dc.identifier.pubmedid29463593-
dc.type.austinJournal Article-
local.name.researcherDijkstra, Christine
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

152
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.